GlassScriptPhysician profile
Charanjit Kapoor
NPI 1700872223
$12,128.02
in general payments reported to CMS, 2019-2025
34 companies · $1,776 in 2025
The $1,776 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,188 · 2020: $582 · 2021: $1,849 · 2022: $2,148 · 2023: $2,417 · 2024: $2,168 · 2025: $1,776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,361.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,312.11 | 2019-2025 | Cardiomems, Jot Dx, Mitraclip |
| Boston Scientific Corporation | $1,709.87 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman, Accolade Sr |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,312.85 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $944.83 | 2019-2025 | |
| Amgen INC. | $685.23 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $568.50 | 2021-2023 | Micra |
| Edwards Lifesciences Corporation | $496.49 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $449.94 | 2023-2025 | Jardiance |
| Kestra Medical Technology Services, INC. | $414.41 | 2022-2025 | Assure Wcd |
| Abiomed | $411.20 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $403.77 | 2021-2025 | Verquvo, Capvaxive |
| Heartflow, INC. | $317.10 | 2023-2025 | Ffrct |
| Sanofi-Aventis U.S. LLC | $277.96 | 2019-2023 | |
| Pfizer INC. | $246.04 | 2019-2025 | |
| Philips North America LLC | $179.68 | 2022-2024 | (5091) Amb Mon & Diag Und |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $176.92 | 2019-2025 | Opsumit, Uptravi |
| W. L. Gore & Associates, INC. | $168.58 | 2023 | Gore Viabahn Endoprosthesis |
| Impulse Dynamics (USA) INC. | $160.49 | 2022-2023 | Optimizer |
| Astrazeneca Pharmaceuticals LP | $143.61 | 2020-2024 | Farxiga |
| Bardy Diagnostics, INC. | $120.00 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $108.32 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $94.62 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $60.48 | 2021-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $58.33 | 2024 | Wegovy |
| Amarin Pharma, INC. | $53.02 | 2020-2021 | |
| Baxter Healthcare | $51.11 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Inspire Medical Systems, INC. | $46.73 | 2024-2025 | Inspire |
| Alnylam Pharmaceuticals INC. | $36.19 | 2022-2024 | Amvuttra |
| Medtronic Vascular, INC. | $29.50 | 2020 | |
| Glaxosmithkline, LLC. | $22.83 | 2025 | Shingrix, Arexvy |
| Zoll Respicardia, INC. | $20.23 | 2024 | Remede System |
| Atricure, INC. | $19.53 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $14.89 | 2023 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $12.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charanjit Kapoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.